Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Polyplus Builds on Research and Commercial mRNA Support Portfolio with in vivo-jetRNA ®+ Transfection Reagent

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Polyplus, a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, continues to build out the mRNA support portfolio. The team has launched in vivo-jetRNA®+ transfection reagent for in vivo mRNA delivery using a preformed liposome.

The new in vivo-jetRNA ®+ transfection reagent an efficient, stable, and safe delivery system leading to 100% mRNA encapsulation for comparable LNP delivery. The ready-to-use format eliminates formulation steps, and the stable liposome size allows for low to high mRNA concentration over time. Applications include prophylactic vaccines, mRNA therapeutics (cancer therapy, rare disease, etc.) and gene editing. A unique feature is the ability to target multiple organs via systemic injection routes in various models with no limitation to liver only.

“Polyplus is known for in vivo delivery expertise, and we have continued to grow this foundational portfolio guided by the voice of the market. In 2007, we launched GMP grade in vivo-jetPEI® reagent,” said Mario Philips, CEO at Polyplus. “In vivo-jetRNA® transfection reagents were then launched in 2019 in ready-to-use and customizable injectable formats for vaccine developers, anti-cancer research, and in vivo functional studies. Now in vivo-jetRNA®+ transfection reagents are being launched to further support the growing demand of mRNA developers.”

Polyplus continues to evolve an upstream solutions portfolio of transfection reagents and DNA vector design services for flexible, reliable, and scalable commercialization support. Come and meet the team around the globe in booth 215 at Cell & Gene Therapy Manufacturing (co-hosted with BPI 2022) during Biotech Week in Boston, MA from 27 to 30 September; in Edinburgh, UK from 11 to 14 October in ESGCT booth 9; and at the Cell & Gene Meeting on the Mesa from 11 to 13 October in Carlsbad, CA.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine